Yahoo Web Search

Search results

1. pubmed.ncbi.nlm.nih.gov › 37861218Tarlatamab for Patients with Previously Treated Small-Cell ...

   pubmed.ncbi.nlm.nih.gov › 37861218

   Nov 30, 2023 · Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified.

2. www.nejm.org › doi › fullTarlatamab for Patients with Previously Treated Small-Cell ...

   www.nejm.org › doi › full

   Oct 20, 2023 · Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell ...

3. Images

   • 
   • 
   • 
   • 
   • 
   • 

   View all

4. www.nejm.org › doi › supplSupplementary Appendix - The New England Journal of Medicine

   www.nejm.org › doi › suppl

   Supplement to: Ahn M-J, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389:2063-75. DOI: 10.1056/NEJMoa2307980

5. ascopubs.org › doi › 10Randomized phase 3 study of tarlatamab, a DLL3-targeting ...

   ascopubs.org › doi › 10

   May 31, 2023 · Methods: NCT05740566 is a randomized, open-label, phase 3 study of tarlatamab compared with standard of care (SOC) in ~700 patients with relapsed SCLC after platinum-based first-line chemotherapy.

6. www.aiom.it › en › tarlatamab-for-patients-withTarlatamab for Patients with Previously Treated Small-Cell ...

   www.aiom.it › en › tarlatamab-for-patients-with

   • Cached

   Jan 16, 2024 · The New England Journal of Medicine, 2023 Nov. 30. Abstract link. Copyright © 2023 Massachusetts Medical Society. Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Oscar Juan-Vidal, Sabin Handzhiev, Hiroki Izumi…

7. ascopubs.org › doi › absLazertinib Versus Gefitinib as First-Line Treatment in ...

   ascopubs.org › doi › abs

   Jun 28, 2023 · June 28, 2023. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301. Authors: Byoung Chul Cho, MD, PhD.

8. embargoed.www.thelancet.com › pdfs › journalsOsimertinib plus savolitinib in patients with EGFR mutation ...

   embargoed.www.thelancet.com › pdfs › journals

   Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.